<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3664">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04439071</url>
  </required_header>
  <id_info>
    <org_study_id>PTC299-VIR-015-COV19</org_study_id>
    <secondary_id>2020-001872-13</secondary_id>
    <nct_id>NCT04439071</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19)</brief_title>
  <acronym>FITE19</acronym>
  <official_title>Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult&#xD;
      participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from Randomization to Respiratory Improvement</measure>
    <time_frame>up to Day 28</time_frame>
    <description>Respiratory improvement is defined as sustained peripheral oxygen saturation (SpO2) ≥94% on room air.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Invasive Ventilation</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Supplemental Oxygen or Non-Invasive Ventilation in Participants who did not Require Supplemental Oxygen at Baseline</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from Randomization to Defervescence in Participants Presenting With Fever at Enrollment (Temperature of ≥37.6℃ Axilla, ≥38.0℃ Oral, or ≥38.6°C Tympanic or Rectal)</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from Randomization to Respiratory Rate ≤ 24 Breaths per Minute on Room Air</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from Randomization to Cough Reported as Mild or Absent</measure>
    <time_frame>up to Day 28</time_frame>
    <description>Cough will be rated on a scale of severe, moderate, mild, absent, in those with cough at enrollment rated severe or moderate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from Randomization to Dyspnea Reported as Mild or Absent</measure>
    <time_frame>up to Day 28</time_frame>
    <description>Dyspnea will be rated on a scale of severe, moderate, mild, absent, in those with dyspnea at enrollment rated as severe or moderate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Immune Responses</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Viral Load</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Mortalities</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Pneumonia</condition>
  <condition>COVID-19</condition>
  <condition>Coronavirus</condition>
  <arm_group>
    <arm_group_label>PTC299 + Standard of Care (SOC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PTC299 at 200 milligrams (mg), administered orally, twice daily (BID) on Days 1 to 7, then at 50 mg administered orally, once daily (QD) on Days 8 to 14.&#xD;
SOC will also be administered according to local, written policies or guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive PTC299-matching placebo administered orally, BID on Days 1 to 7, then administered orally, QD on Days 8 to 14.&#xD;
SOC will also be administered according to local, written policies or guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTC299</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>PTC299 + Standard of Care (SOC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SOC</intervention_name>
    <description>As defined per local written policies or guidelines.</description>
    <arm_group_label>PTC299 + Standard of Care (SOC)</arm_group_label>
    <arm_group_label>Placebo + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Placebo + SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent document(s).&#xD;
&#xD;
          -  Agrees to the collection of nasopharyngeal swabs and venous blood and all other&#xD;
             protocol-specified procedures.&#xD;
&#xD;
          -  Male or non-pregnant female adult ≥18 years of age at time of enrollment.&#xD;
&#xD;
          -  Hospitalized and has laboratory-confirmed infection with severe acute respiratory&#xD;
             syndrome coronavirus 2 (SARS-CoV-2).&#xD;
&#xD;
          -  Symptom onset was ≤7 days prior to screening.&#xD;
&#xD;
          -  Has oxygen saturation SpO2 &lt;94% on room air.&#xD;
&#xD;
          -  Has at least one of a respiratory rate &gt;24 breaths/minute or cough.&#xD;
&#xD;
          -  Lung involvement as confirmed by radiographic infiltrates observed on imaging (chest&#xD;
             X-ray, computed tomography (CT) scan, or an equivalent test).&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test at screening and&#xD;
             agree to abstinence or the use at least one primary form of contraception for the&#xD;
             duration of the study following discharge from the hospital, and for up to 50 days&#xD;
             after the last dose of study drug (acceptable methods will be determined by the site).&#xD;
&#xD;
          -  Men sexually active with women of childbearing potential who have not had a vasectomy&#xD;
             must agree to use a barrier method of birth control during the study following&#xD;
             discharge from the hospital and for up to 50 days after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requires mechanical ventilation.&#xD;
&#xD;
          -  Current participation in any other interventional study.&#xD;
&#xD;
          -  Alanine transaminase/aspartate transaminase levels ≥3 times the upper limit of normal&#xD;
             (×ULN) or total bilirubin (Tbili) ≥2×ULN.&#xD;
&#xD;
          -  Lymphocyte count &lt;500 lymphocytes/microliter (μL) or hemoglobin &lt;11 grams/deciliter&#xD;
             (g/dL).&#xD;
&#xD;
          -  Stage 4 severe chronic kidney disease or requiring dialysis (that is, estimated&#xD;
             glomerular filtration rate &lt;30).&#xD;
&#xD;
          -  Any other condition, that in the opinion of the Investigator, may be cause to exclude&#xD;
             the participant from the study.&#xD;
&#xD;
          -  Use of steroids (except dexamethasone), sensitive CYP2D6 substrates, CYP2C inducers,&#xD;
             IL-6 neutralizing antibodies, IL-6 receptor inhibitors, or any investigational&#xD;
             therapy.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Anticipated transfer to another hospital which is not a study site within 72 hours.&#xD;
&#xD;
          -  Known allergy to PTC299 or excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quintus Ngumah, OD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>PTC Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-866-562-4620</phone>
    <email>medinfo@ptcbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Salisbury VA Medical Center</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ralph H. Johnson VA Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia VA Health Care System</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>02145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital</name>
      <address>
        <city>St. Albans</city>
        <state>Victoria</state>
        <zip>03021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vera Cruz</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30190-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina da UNESP Campus de Botucatu</name>
      <address>
        <city>Botucatu</city>
        <state>SP</state>
        <zip>18618-686</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Guilherme Alvaro</name>
      <address>
        <city>Santos</city>
        <state>SP</state>
        <zip>11045-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Casa de Misecórdia de Sorocoba</name>
      <address>
        <city>Sorocaba</city>
        <state>SP</state>
        <zip>18013-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Infectologia Emílio Ribas</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01246-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Real e Benemérita Associação Portuguesa de Beneficência</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01323-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Alemao Oswaldo Cruz</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01508-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Escola Paulista de Medicina (UNIFESP)</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04023-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

